<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702685</url>
  </required_header>
  <id_info>
    <org_study_id>ESP1</org_study_id>
    <nct_id>NCT04702685</nct_id>
  </id_info>
  <brief_title>Erector Spinae Plane Block With Ropivacaine for Major Upper Abdominal Surgery</brief_title>
  <official_title>A Single Center, Randomized, Parallel Group Study to Evaluate the Efficacy of Ropivacaine Administered by Ultrasound-guided Erector Spinae Plane Block for Major Upper Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nazarbayev University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Oncology and Transplantology Center, Kazakhstan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nazarbayev University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single-centre, randomized, controlled, open-label, evaluator-blinded,&#xD;
      superiority trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to establish whether ESP ropivacaine reduces post-operative opioid&#xD;
      use and improves pain rating post-operatively. The secondary objectives include adverse event&#xD;
      incidence, time to ambulation and time to discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Bandage with tape will be placed over the presumed site of anesthetic injection</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean cumulative opioid consumption up to 24 hours after surgery</measure>
    <time_frame>24 hours post-operation</time_frame>
    <description>Cumulative opioid consumption will be recorded for 24 hours following surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative pain score</measure>
    <time_frame>Measured post-operatively at 0, 2, 4, 6, 8, 10, 12, 16, 20, 24 hours after surgery.</time_frame>
    <description>Numerical rating scale (0= no pain; 10= worst pain imaginable) will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ambulation</measure>
    <time_frame>Between surgery and discharge from hospital, expected time is between 1 day to 1 week</time_frame>
    <description>The time that the patient is able to walk independently, after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>Expected time to discharge is up to 2 weeks</time_frame>
    <description>From time of surgery completion to discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of NSAIDs post surgery</measure>
    <time_frame>Total dose used during the 24 hour period after surgery.</time_frame>
    <description>Dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ropivacaine 0.5% - 20 ml will be administered as erector spinae plane block under ultrasound guidance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No injection. Bandage will be placed over the presumed site of injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Local anesthetic for injection</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Bandage will be placed in the presumed injection site while patients in under general anesthesia</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults who are scheduled to undergo major upper abdominal surgery (e.g.&#xD;
             Pancreato-duodenal resection). If enrollment rates are insufficient, patients&#xD;
             undergoing other major upper abdominal surgery will be enrolled (e.g in the&#xD;
             supraumbilical area: liver resection, colon resection; Whipple procedure;&#xD;
             gastrectomy).&#xD;
&#xD;
          2. Males or females 18-70 years of age&#xD;
&#xD;
          3. American Society of Anesthesiologists physical status class I,II, III&#xD;
&#xD;
          4. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing emergency surgery&#xD;
&#xD;
          2. Decompensated cardiovascular disease (e.g. left ventricular ejection fraction ≤40%),&#xD;
             chronic heart failure, rhythm and conduction disorders, coagulopathies)&#xD;
&#xD;
          3. Comorbid obesity (BMI≥35kg/m2)&#xD;
&#xD;
          4. Anomalies of vertebral column&#xD;
&#xD;
          5. Use of anticoagulants and patients with hypocoagulable conditions&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Physician preference for therapeutic anticoagulation&#xD;
&#xD;
          8. Infection of skin at site of needle puncture&#xD;
&#xD;
          9. Known allergies to study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip la Fleur, RPh MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>philip.lafleur@nu.edu.kz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dmitry Viderman, MD</last_name>
    <phone>+77055426716</phone>
    <email>dmitry.viderman@nu.edu.kz</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Center for Oncology</name>
      <address>
        <city>Astana</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ropivacaine</keyword>
  <keyword>major upper abdominal surgery</keyword>
  <keyword>supraumbilical</keyword>
  <keyword>liver resection</keyword>
  <keyword>colon resection</keyword>
  <keyword>Whipple procedure</keyword>
  <keyword>gastrectomy</keyword>
  <keyword>anesthetics, local</keyword>
  <keyword>erector spinae plane block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon request, we will share information with other researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Q3 and Q4 2021</ipd_time_frame>
    <ipd_access_criteria>Researchers on staff at an accredited university</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

